NRX Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing innovative treatments for central nervous system disorders and life-threatening pulmonary diseases. Their products include ZYESAMI, a drug being studied for COVID-19 respiratory failure, as well as oral therapeutics for bipolar depression and suicidal behavior. Founded in 2015, the company is headquartered in Wilmington, Delaware.